Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-14 21:56:09 - browse：3358

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

The battle over 'scope creep' and who gets to be called 'doctor'

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

The battle over 'scope creep' and who gets to be called 'doctor'

The haunting brain science of long Covid

In the gardens at Boston Children's Hospital, families find sanctuary

hotspot

Wikipedia

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Americans' trust in science, scientist continues decline: Report

DIEP, the 'gold standard' of breast reconstruction, is under threat

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Alkermes shareholders re

Pfizer plans to depart BIO

Novavax promises a turnaround & Lilly roils the obesity market

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Sports medicine is finally prioritizing gender equality

Pfizer plans to depart BIO

hotspot

New Alzheimer's drugs heat up race for early detection blood tests

'Investigate these claims': UFO transparency at center of House hearing

What PEPFAR has meant on the ground in Ukraine

Will the FTC rein in IQVIA's health data empire?

Teach medical students about patients with intellectual disabilities

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

knowledge

explore

focus

hotspot